Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2017 Nov 13;17(1):297–305. doi: 10.1158/1535-7163.MCT-17-0360

Figure 3. Overall potential actionability of characterized alterations based on available agents.

Figure 3

Almost all patients (122/123) with characterized alterations(s) had one or more targeted therapy(ies) available, either through an on-label drug, an off-label drug, or a clinical trial. For patients who had multiple therapies available, FDA approved agents were prioritized over experimental drugs. Amongst FDA approved agents, on-label drugs were prioritized over off-label drugs.